Stoke Therapeutics, Inc. (STOK) Quick Ratio
- Quick ratio · latest quarter: Value 7.15×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 7.15× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $300.00M ÷ $41.93M ≈ 7.15× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 300.00M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 41.93M USD | Liabilities, Current |
| Cash and equivalents | 110.00M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 182.81M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 7.18M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $300.00M | $41.93M | $110.00M | $182.81M | $7.18M | (m) | 7.15× |
| 2026-03-31 | $348.00M | $40.81M | $155.66M | $187.89M | $4.45M | (m) | 8.53× |
| 2025-12-31 | $290.61M | $57.88M | $84.22M | $200.45M | $5.94M | (m) | 5.02× |
| 2025-09-30 | $257.56M | $41.73M | $83.39M | $164.92M | $9.25M | (m) | 6.17× |
| 2025-06-30 | (m) | $38.68M | $101.47M | $146.24M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $44.69M | $274.82M | $82.51M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $40.06M | $127.98M | $88.92M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $49.87M | $150.02M | $89.18M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $44.50M | $193.48M | $88.51M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $35.59M | $178.58M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $30.82M | $191.44M | $9.95M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $25.20M | $189.98M | $24.74M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $21.84M | $192.06M | $39.39M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $31.53M | $190.34M | $63.33M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $31.39M | $113.56M | $116.04M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $28.80M | $113.40M | $138.26M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $27.65M | $67.75M | $207.88M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $22.91M | $84.11M | $209.10M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $17.14M | $144.90M | $74.92M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $11.88M | $149.04M | $87.12M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $8.20M | $169.07M | $82.16M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $6.11M | $267.51M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $11.43M | $287.31M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $6.74M | $191.46M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $5.80M | $201.93M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $5.46M | $211.29M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $4.10M | $222.47M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $4.92M | $233.05M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $4.82M | $242.68M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $98.65M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.47M | $105.40M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $19.37M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $9.55M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |